Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s Why

Posted by Brenda Bartman on May 21st, 2026

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $49.48, but opened at $45.93. Nanobiotix shares last traded at $45.1750, with a volume of 10,304 shares changing hands.

Analysts Set New Price Targets

Several research firms have recently weighed in on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim upped their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. UBS Group upped their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Monday. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Read Our Latest Stock Report on NBTX

Nanobiotix Stock Down 6.6%

The stock’s 50-day moving average price is $35.66 and its 200 day moving average price is $27.42.

Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. On average, research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.19 EPS for the current year.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. Optiver Holding B.V. bought a new stake in Nanobiotix during the third quarter worth $101,000. Marshall Wace LLP bought a new stake in Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth $390,000. 38.81% of the stock is owned by institutional investors.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.